aspartate transaminase to platelet ratio index (apri) to assess liver fibrosis in patients with chronic liver disease

Aspartate transaminase to platelet ratio index (APRI) to assess liver fibrosis in patients with chronic liver disease

In patients with chronic liver disease (CLD), liver biopsy is currently an indispensable reference method to assess inflammatory activity and fibrosis stage and thus to estimate prognosis and guide management decisions in such patients. Given that the presence of advanced fibrosis is a predictor of nonresponse, the decision (1) to begin antiviral therapy in cases of chronic viral hepatitis is h...

noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (apri): usefulness in patients with chronic liver disease

Noninvasive assessment of liver fibrosis with aspartate transaminase to platelet ratio index (APRI)

Adler M. Noninvasive assessment of liver fibrosis with aspartate transaminase to platelet ratio index (APRI). In chronic liver diseases, the management of patients must include a determination of the stage of fibrosis (to select specific therapies), a prognosis, the prevention of complications, and the surveillance of the disease. Over the past several years, significant progress has been made ...

Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease

BACKGROUND The aspartate aminotransferases (AST) to platelet ratio index (APRI) may serve as a noninvasive marker to assess liver fibrosis. OBJECTIVES To assess the diagnostic ability of the APRI for prediction of fibrosis in patients with chronic hepatitis B (CHB), chronic hepatitis C (CHC), and non-alcoholic fatty liver disease (NAFLD). PATIENTS AND METHODS This retrospective study includ...

Commentary on: Noninvasive assessment of liver fibrosis using aspartate transaminase to platelet ratio index (APRI) in adult patients with chronic liver disease

We enjoyed reading the excellent article by Yilmaz and colleagues on noninvasive assessment of liver fibrosis using aspartate transaminase to platelet ratio index (APRI) in adult patients with chronic liver disease (CLD) (1). They performed their tests on adults with chronic hepatitis C (CHC), B (CHB), and non-alcoholic fatty liver disease (NAFLD). We definitely need to develop serological mark...

Commentary on: Aspartate transaminase to platelet ratio index (APRI): A simple noninvasive index assessing liver fibrosis in patients with chronic liver diseases

Hepatitis Monthly has recently published an interesting and practically valuable original report from Yilmaz, et al. (1). That was a retrospective study investigating the ability of the aspartate transaminase to platelet ratio index (APRI) in diagnosing and predicting the extent of fibrosis in patients with chronic hepatitis B (CHB), chronic hepatitis C (CHC), and non-alcoholic fatty liver dise...